Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Name: Kaimen Rigor review — Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
Item: Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
Rating: 96
Author: Alpha1

Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, Xu Y, Kuang H, Shi L, Xue Y, Feng B, Zhu D, Wang G, Yang J, Xiao X, Yu X, Zhou J, Bao Y, Su Q, Lyu M, Li X, Zhang H, Li X

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, Xu Y, Kuang H, Shi L, Xue Y, Feng B, Zhu D, Wang G, Yang J, Xiao X, Yu X, Zhou J, Bao Y, Su Q, Lyu M, Li X, Zhang H, Li X

Read full text (PMC)

DOI

10.1136/bmj-2024-081820

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/aad5a84a-0f2d-484f-bea7-309fede4cb03" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/aad5a84a-0f2d-484f-bea7-309fede4cb03/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

7e9eb6ed9f5b57e343ad741e01c98905ea5f2729d707a5a439df3109cb6e1eb1

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, Xu Y, Kuang H, Shi L, Xue Y, Feng B, Zhu D, Wang G, Yang J, Xiao X, Yu X, Zhou J, Bao Y, Su Q, Lyu M, Li X, Zhang H, Li X

Paper source

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 52 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is diabetes remission defined by glycated hemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of antidiabetic drugs for at least 2 months. This is a surrogate endpoint (glycemic control) rather than a hard clinical outcome. The paper does not provide evidence linking this surrogate to long-term clinical outcomes such as mortality or macrovascular complications, nor does it demonstrate target engagement at the tested dose beyond the mechanism of SGLT2 inhibition.
“Primary outcome: incidence of diabetes remission (defined as glycated haemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of all antidiabetic drugs for at least 2 months)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a remission rate of 44% in the dapagliflozin group vs 28% in placebo, with a risk ratio of 1.56. While statistically significant, the absolute difference is 16 percentage points, and the effect size is not anchored to a minimal clinically important difference or long-term clinical benefit. The remission definition is based on a short-term surrogate (2 months off drugs) and may not reflect durable remission or improved clinical outcomes.
“Remission of diabetes was achieved in 44% (73/165) of patients in the dapagliflozin group and 28% (46/163) of patients in the placebo group (risk ratio 1.56, 95% confidence interval (CI) 1.17 to 2.09; P=0.002)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomised controlled trial with rigorous design, clear reporting of methods and results, and appropriate ethical approvals. The main weakness is the vague data availability statement, which lacks a concrete access mechanism, and minor copyedit issues.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence was present. The statistics verification component checked only 2 tests (those with test statistics or effect estimates with CIs) and found them consistent; other reported statistics were not machine-verified. The citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Prior research is cited (DiRECT trial, bariatric surgery, SGLT-2 inhibitor mechanisms) with strengths and limitations acknowledged (e.g., very low energy diet challenge, surgery risks). The rationale logically connects energy deficit from dapagliflozin plus calorie restriction to remission. Limitations of prior approaches are addressed by proposing a more practicable regimen.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific premise, citing prior work (DiRECT, bariatric surgery, SGLT-2 inhibitors) and a logical hypothesis linking energy deficit to diabetes remission.

Evidence

paraphrase[Introduction, paragraph 1]

“In the DiRECT trial, participants who had had diabetes for up to six years underwent an intensive dietary intervention. Diabetes remission ... was achieved in 46% of the intervention group, with a mean body weight reduction of 10%. However, the strategy of a very low energy diet in routine care settings remains a challenge.”

“Thus, we hypothesised that dapagliflozin plus calorie restriction could achieve greater energy deficit and greater reduction of hyperglycaemia than calorie restriction alone and could lead to remission of diabetes in a generally acceptable way.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The study builds on prior evidence (DiRECT, bariatric surgery, SGLT-2 inhibitor mechanisms) and provides a clear rationale for the hypothesis.

Evidence

paraphrase[Introduction, paragraph 1]

IntroductionFind in source

“However, the strategy of a very low energy diet in routine care settings remains a challenge.”

Introduction ¶1Find in source

Randomisation method (centralised IWRS, block size 4, stratified by metformin) and unit (participant) are reported. Blinding is described (identical tablets, masked investigators/patients). Power analysis is provided (80% power, 12.3% difference, 20% dropout). Inclusion/exclusion criteria are pre-specified. Outlier handling is addressed via ITT and multiple imputation for missing data. Controls are inherent (placebo group). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: centralised web-based randomisation with stratification, double-blinding, a priori sample size calculation, pre-specified inclusion/exclusion criteria, and ITT analysis.

Evidence

“Randomisation was achieved by an independent third party (Trial Data Pharmaceutical Technology; Shanghai, China) using a centralised interactive web based randomisation system (Trial Data IWRS) with block size of four and stratification according to metformin treatment at screening (yes or no).”

MethodsFind in source

“Dapagliflozin and placebo tablets were identical in size, shape, colour, and appearance, were packaged in identical bottles, and were administered in the same dosage and route. The investigators, clinical staff, dietitian, and patients were masked to treatment throughout the study.”

MethodsFind in source

“The sample size calculation suggested that 328 participants (164 per group) would provide 80% power to detect a significant difference (12.3%) in the remission rate between the dapagliflozin group and the placebo group at a significance level of 0.05 using a two tailed test, assuming an anticipated dropout rate of less than 20%.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial is well-designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

MethodsFind in source

“The investigators, clinical staff, dietitian, and patients were masked to treatment throughout the study.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported (66% male overall; 68% vs 65% per group). Age, weight, BMI, blood pressure, diabetes duration, and comorbidities (hypertension) are reported. Species/strain/housing are not applicable for a human trial. Demographics are adequately reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Human demographics (age, sex, BMI, comorbidities) are reported in Table 1; sex is reported and both sexes are enrolled, so no single-sex justification is needed.

Evidence

“The mean age of the participants was 46.7 years, 66% (218/328) were men, and the mean body mass index was 28.2.”

Table 1Find in source

“No (%) hypertension | 90 (55) | 93 (57)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, BMI, and comorbidities.

Evidence

“The mean age of the participants was 46.7 years, 66% (218/328) were men, and the mean body mass index was 28.2.”

ResultsFind in source

“Mean (SD) age, years | 46.4 (10.4) | 47.1 (11.4)”

Table 1Find in source

“No (%) hypertension | 90 (55) | 93 (57)”

Table 1Find in source

The ethics statement names the approving bodies (ethics committees at each centre) and states written informed consent was obtained. Regulatory compliance is supported by trial registration (ClinicalTrials.gov NCT04004793) and adherence to ICMJE disclosure. The statement is adequate.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval from each centre's ethics committee and written informed consent are reported; regulatory compliance is implied by trial registration and ICMJE disclosure.

Evidence

“The study protocol and amendments were reviewed and approved by the ethics committees at each centre. All the participants provided written informed consent.”

EthicsFind in source

“Trial registration ClinicalTrials.gov NCT04004793 .”

AbstractFind in source

PASSReviewer 2· 90% conf

Ethical approval and informed consent are adequately reported.

Evidence

“The study protocol and amendments were reviewed and approved by the ethics committees at each centre.”

EthicsFind in source

“All the participants provided written informed consent.”

EthicsFind in source

absence[Ethics statements]

Regulatory compliance is not explicitly named.

Dapagliflozin is identified by name and dose (10 mg/day); placebo is described as identical tablets. Protein shakes (Nutriease, Zhejiang Nutriease, China) are identified. SAS version 9.4 is identified. No antibodies, cell lines, or mycoplasma testing are applicable. The trial is scored because the investigational product is a key resource.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (dapagliflozin 10 mg) and comparator (placebo) are identified with dose and regimen; protein shakes are named with manufacturer; statistical software is identified.

Evidence

“Eligible participants were randomly assigned in a one-to-one ratio to receive 10 mg of dapagliflozin or placebo per day for 12 months”

MethodsFind in source

“Participants were provided with protein shakes (Nutriease, Zhejiang Nutriease, China) twice a day for the first three months”

MethodsFind in source

“We used SAS version 9.4 for all statistical analyses.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (dapagliflozin) and key software are identified; other bench resources are not applicable.

Evidence

“Eligible participants were randomly assigned in a one-to-one ratio to receive 10 mg of dapagliflozin or placebo per day for 12 months”

MethodsFind in source

“Participants were provided with protein shakes (Nutriease, Zhejiang Nutriease, China) twice a day for the first three months”

MethodsFind in source

“We used SAS version 9.4 for all statistical analyses.”

Statistical analysisFind in source

Primary analysis uses Cochran-Mantel-Haenszel test; secondary outcomes use mixed effects model with autoregressive correlation. Exact p-values are reported (e.g., P=0.002). Effect sizes with 95% CIs are reported for all outcomes. Assumptions are handled by design (mixed model, multiple imputation). Data presentation includes flow diagram, baseline table, and per-group n. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, exact p-values are reported, effect sizes with CIs are given, software is identified, and data presentation follows clinical trial norms.

Evidence

“For the primary outcome, we used a Cochran-Mantel-Haenszel test, stratified according to whether participants were treated with metformin at baseline, to estimate the risk ratio and corresponding 95% confidence interval (CI).”

Statistical analysisFind in source

paraphrase[Results, Remission of diabetes; Table 2]

“The risk ratio for diabetes remission stratified by whether participants were treated with metformin at baseline was 1.56 (95% CI 1.17 to 2.09) ... P=0.002”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described; p-values are exact and effect sizes with CIs are reported.

Evidence

Statistical analysisFind in source

“Remission of diabetes was achieved in 44% (73/165) of patients in the dapagliflozin group and 28% (46/163) of patients in the placebo group (risk ratio 1.56, 95% confidence interval (CI) 1.17 to 2.09; P=0.002)”

AbstractFind in source

“Change in body weight, kg | −5.0 (4.5) | −3.2 (3.8) | −1.3 (−1.9 to −0.7) | <0.001”

Table 2Find in source

The data availability statement is present but lacks a concrete access mechanism (no repository, platform, or data-access committee). For patient-level data, managed access is acceptable, but the statement is too vague. No code sharing is reported, but no bespoke code is mentioned.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data availability statement exists but is vague ('available from the corresponding author on reasonable request') with no platform or conditions; no code sharing is reported.

Evidence

“Data from this study can be requested from the correspond”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement exists but is vague, lacking a concrete access mechanism.

Evidence

“Data from this study can be requested from the correspond”

Data availabilityFind in source

Methods are comprehensive (diet, exercise, drug discontinuation criteria). Trial registration number is provided. Limitations are explicitly discussed (generalisability, remission definition, DXA availability, energy expenditure). Conclusions are proportional to the results. Funding sources and COI are disclosed. No reporting guideline checklist is mentioned, but this is not a fail for a clinical trial.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Methods are detailed, trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04004793 .”

AbstractFind in source

“Firstly, our findings cannot be generalised to patients with a duration of type 2 diabetes of more than six years or to populations of other races or ethnic groups.”

LimitationsFind in source

“Funding: This study was funded by grants from the National Nature Science Foundation of China (32241011, 82330024, 92357306) and National Nature Science Foundation of China for Distinguished Young Scholars (82325011), and partially by a grant from AstraZeneca (ESR-18-13952).”

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04004793 .”

AbstractFind in source

“The study had some limitations. Firstly, our findings cannot be generalised to patients with a duration of type 2 diabetes of more than six years or to populations of other races or ethnic groups.”

LimitationsFind in source

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 16 references by DOI: 15 verified — 1 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the vague data availability statement and the minor copyedit issues as the only notable gaps. No erratum or re-analysis is warranted based on the evidence reviewed.

1.
HIGHdata code
Replace the vague data availability statement with a concrete access mechanism, such as a named data-access committee or platform (e.g., YODA, Vivli) with conditions and timeframe.
The current statement ('available from the corresponding author on reasonable request') lacks transparency and is a common reviewer concern.
2.
MEDIUMreporting
Explicitly state adherence to the CONSORT reporting guideline in the Methods or as a supplementary checklist.
Referencing CONSORT strengthens reporting transparency and is expected for clinical trials.
3.
MEDIUMethics
Add a statement on regulatory compliance (e.g., Declaration of Helsinki) in the Ethics section.
Explicitly naming the ethical standard enhances completeness, though approval is already stated.
4.
MEDIUMdata code
If bespoke analysis code was used, deposit it in a public repository (e.g., Zenodo, GitHub) with a DOI and reference it in the manuscript.
Code sharing improves reproducibility and is increasingly expected.
5.
MEDIUMreporting
Clarify the race/ethnicity breakdown of participants in the demographics, as the study is conducted in China but does not explicitly state ethnicity.
Explicit demographic reporting improves generalisability assessment.
6.
LOWcopyedit
Add 'the' before 'remission' in the Abstract Objective for grammatical flow.
Minor grammatical improvement.
7.
LOWcopyedit
Use 'two-sided' consistently with hyphenation in the Methods, Statistical analysis section.
Hyphenation inconsistency is a minor copyedit issue.
8.
LOWcopyedit
Clarify why the median intervention duration differs between groups (9 vs 12 months) in the Results, Remission of diabetes section.
Potential reader confusion; explain early discontinuation or other reasons.

Full text (34,638 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, Xu Y, Kuang H, Shi L, Xue Y, Feng B, Zhu D, Wang G, Yang J, Xiao X, Yu X, Zhou J, Bao Y, Su Q, Lyu M, Li X, Zhang H, Li X

Read full text (PMC)

DOI

10.1136/bmj-2024-081820

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/aad5a84a-0f2d-484f-bea7-309fede4cb03" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/aad5a84a-0f2d-484f-bea7-309fede4cb03/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

7e9eb6ed9f5b57e343ad741e01c98905ea5f2729d707a5a439df3109cb6e1eb1

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 52 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is diabetes remission defined by glycated hemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of antidiabetic drugs for at least 2 months. This is a surrogate endpoint (glycemic control) rather than a hard clinical outcome. The paper does not provide evidence linking this surrogate to long-term clinical outcomes such as mortality or macrovascular complications, nor does it demonstrate target engagement at the tested dose beyond the mechanism of SGLT2 inhibition.
“Primary outcome: incidence of diabetes remission (defined as glycated haemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of all antidiabetic drugs for at least 2 months)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a remission rate of 44% in the dapagliflozin group vs 28% in placebo, with a risk ratio of 1.56. While statistically significant, the absolute difference is 16 percentage points, and the effect size is not anchored to a minimal clinically important difference or long-term clinical benefit. The remission definition is based on a short-term surrogate (2 months off drugs) and may not reflect durable remission or improved clinical outcomes.
“Remission of diabetes was achieved in 44% (73/165) of patients in the dapagliflozin group and 28% (46/163) of patients in the placebo group (risk ratio 1.56, 95% confidence interval (CI) 1.17 to 2.09; P=0.002)”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 1 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific premise, citing prior work (DiRECT, bariatric surgery, SGLT-2 inhibitors) and a logical hypothesis linking energy deficit to diabetes remission.

Evidence

paraphrase[Introduction, paragraph 1]

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The study builds on prior evidence (DiRECT, bariatric surgery, SGLT-2 inhibitor mechanisms) and provides a clear rationale for the hypothesis.

Evidence

paraphrase[Introduction, paragraph 1]

IntroductionFind in source

“However, the strategy of a very low energy diet in routine care settings remains a challenge.”

Introduction ¶1Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: centralised web-based randomisation with stratification, double-blinding, a priori sample size calculation, pre-specified inclusion/exclusion criteria, and ITT analysis.

Evidence

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial is well-designed with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

MethodsFind in source

“The investigators, clinical staff, dietitian, and patients were masked to treatment throughout the study.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Human demographics (age, sex, BMI, comorbidities) are reported in Table 1; sex is reported and both sexes are enrolled, so no single-sex justification is needed.

Evidence

“The mean age of the participants was 46.7 years, 66% (218/328) were men, and the mean body mass index was 28.2.”

Table 1Find in source

“No (%) hypertension | 90 (55) | 93 (57)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, BMI, and comorbidities.

Evidence

“The mean age of the participants was 46.7 years, 66% (218/328) were men, and the mean body mass index was 28.2.”

ResultsFind in source

“Mean (SD) age, years | 46.4 (10.4) | 47.1 (11.4)”

Table 1Find in source

“No (%) hypertension | 90 (55) | 93 (57)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval from each centre's ethics committee and written informed consent are reported; regulatory compliance is implied by trial registration and ICMJE disclosure.

Evidence

“The study protocol and amendments were reviewed and approved by the ethics committees at each centre. All the participants provided written informed consent.”

EthicsFind in source

“Trial registration ClinicalTrials.gov NCT04004793 .”

AbstractFind in source

PASSReviewer 2· 90% conf

Ethical approval and informed consent are adequately reported.

Evidence

“The study protocol and amendments were reviewed and approved by the ethics committees at each centre.”

EthicsFind in source

“All the participants provided written informed consent.”

EthicsFind in source

absence[Ethics statements]

Regulatory compliance is not explicitly named.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (dapagliflozin 10 mg) and comparator (placebo) are identified with dose and regimen; protein shakes are named with manufacturer; statistical software is identified.

Evidence

“Eligible participants were randomly assigned in a one-to-one ratio to receive 10 mg of dapagliflozin or placebo per day for 12 months”

MethodsFind in source

“Participants were provided with protein shakes (Nutriease, Zhejiang Nutriease, China) twice a day for the first three months”

MethodsFind in source

“We used SAS version 9.4 for all statistical analyses.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (dapagliflozin) and key software are identified; other bench resources are not applicable.

Evidence

“Eligible participants were randomly assigned in a one-to-one ratio to receive 10 mg of dapagliflozin or placebo per day for 12 months”

MethodsFind in source

“Participants were provided with protein shakes (Nutriease, Zhejiang Nutriease, China) twice a day for the first three months”

MethodsFind in source

“We used SAS version 9.4 for all statistical analyses.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical tests are named, exact p-values are reported, effect sizes with CIs are given, software is identified, and data presentation follows clinical trial norms.

Evidence

Statistical analysisFind in source

paraphrase[Results, Remission of diabetes; Table 2]

“The risk ratio for diabetes remission stratified by whether participants were treated with metformin at baseline was 1.56 (95% CI 1.17 to 2.09) ... P=0.002”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described; p-values are exact and effect sizes with CIs are reported.

Evidence

Statistical analysisFind in source

AbstractFind in source

“Change in body weight, kg | −5.0 (4.5) | −3.2 (3.8) | −1.3 (−1.9 to −0.7) | <0.001”

Table 2Find in source

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data availability statement exists but is vague ('available from the corresponding author on reasonable request') with no platform or conditions; no code sharing is reported.

Evidence

“Data from this study can be requested from the correspond”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement exists but is vague, lacking a concrete access mechanism.

Evidence

“Data from this study can be requested from the correspond”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Methods are detailed, trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04004793 .”

AbstractFind in source

“Firstly, our findings cannot be generalised to patients with a duration of type 2 diabetes of more than six years or to populations of other races or ethnic groups.”

LimitationsFind in source

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT04004793 .”

AbstractFind in source

LimitationsFind in source

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 16 references by DOI: 15 verified — 1 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Replace the vague data availability statement with a concrete access mechanism, such as a named data-access committee or platform (e.g., YODA, Vivli) with conditions and timeframe.
The current statement ('available from the corresponding author on reasonable request') lacks transparency and is a common reviewer concern.
2.
MEDIUMreporting
Explicitly state adherence to the CONSORT reporting guideline in the Methods or as a supplementary checklist.
Referencing CONSORT strengthens reporting transparency and is expected for clinical trials.
3.
MEDIUMethics
Add a statement on regulatory compliance (e.g., Declaration of Helsinki) in the Ethics section.
Explicitly naming the ethical standard enhances completeness, though approval is already stated.
4.
MEDIUMdata code
If bespoke analysis code was used, deposit it in a public repository (e.g., Zenodo, GitHub) with a DOI and reference it in the manuscript.
Code sharing improves reproducibility and is increasingly expected.
5.
MEDIUMreporting
Clarify the race/ethnicity breakdown of participants in the demographics, as the study is conducted in China but does not explicitly state ethnicity.
Explicit demographic reporting improves generalisability assessment.
6.
LOWcopyedit
Add 'the' before 'remission' in the Abstract Objective for grammatical flow.
Minor grammatical improvement.
7.
LOWcopyedit
Use 'two-sided' consistently with hyphenation in the Methods, Statistical analysis section.
Hyphenation inconsistency is a minor copyedit issue.
8.
LOWcopyedit
Clarify why the median intervention duration differs between groups (9 vs 12 months) in the Results, Remission of diabetes section.
Potential reader confusion; explain early discontinuation or other reasons.

Full text (34,638 chars)Analyzed: Aug 15, 2026